G Moyle

Summary

Country: UK

Publications

  1. doi request reprint Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection
    Graeme J Moyle
    St Stephens AIDS Research, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    Clin Drug Investig 34:287-96. 2014
  2. pmc NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials
    Stephen Brown
    AIDS Research Alliance, Los Angeles, CA, USA
    AIDS Res Ther 10:5. 2013
  3. doi request reprint A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity
    Graeme J Moyle
    St Stephens Centre, Chelsea and Westminster Hospital, London, UK
    Antivir Ther 17:689-700. 2012
  4. pmc Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up
    Anna A Herasimtschuk
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    J Immune Based Ther Vaccines 6:7. 2008
  5. ncbi request reprint A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy
    G J Moyle
    Chelsen and Westminster Hospital, London, Uned Kingdom
    J Acquir Immune Defic Syndr 33:22-8. 2003
  6. ncbi request reprint Metabolic issues associated with protease inhibitors
    Graeme Moyle
    HIV Medicine, St Stephens Centre, Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 45:S19-26. 2007
  7. ncbi request reprint Once-daily therapy: less is more
    G Moyle
    HIV Research Department, Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 14:1-5. 2003
  8. doi request reprint Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection
    Graeme Moyle
    HIV Research Chelsea and Westminster Hospital, London, United Kingdom
    AIDS Patient Care STDS 22:459-71. 2008
  9. ncbi request reprint Managing HIV lipoatrophy
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    Lancet 363:412-4. 2004
  10. ncbi request reprint Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    Clin Ther 26:92-7. 2004

Detail Information

Publications110 found, 100 shown here

  1. doi request reprint Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection
    Graeme J Moyle
    St Stephens AIDS Research, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    Clin Drug Investig 34:287-96. 2014
    ....
  2. pmc NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: integrated analysis of two phase III, randomized, controlled trials
    Stephen Brown
    AIDS Research Alliance, Los Angeles, CA, USA
    AIDS Res Ther 10:5. 2013
    ..Data from two phase III, double-blind studies were integrated to further analyze the efficacy and safety of NGX-4010 and explore the effect of demographic and baseline factors on NGX-4010 treatment in HIV-DSP...
  3. doi request reprint A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity
    Graeme J Moyle
    St Stephens Centre, Chelsea and Westminster Hospital, London, UK
    Antivir Ther 17:689-700. 2012
    ..Lipoatrophy is associated with long-term thymidine analogue therapy. Individual protease inhibitors (PIs) differ in their effects on lipids and insulin resistance...
  4. pmc Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up
    Anna A Herasimtschuk
    Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK
    J Immune Based Ther Vaccines 6:7. 2008
    ....
  5. ncbi request reprint A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy
    G J Moyle
    Chelsen and Westminster Hospital, London, Uned Kingdom
    J Acquir Immune Defic Syndr 33:22-8. 2003
    ..The mechanisms by which dyslipidemia and lipoatrophy develop during antiretroviral therapy are not clear. No treatment of lipoatrophy is currently established...
  6. ncbi request reprint Metabolic issues associated with protease inhibitors
    Graeme Moyle
    HIV Medicine, St Stephens Centre, Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 45:S19-26. 2007
    ..In addition, drug selection and treatment switching to agents with less impact on metabolic effects can reduce metabolic risk in HIV-positive individuals receiving ART...
  7. ncbi request reprint Once-daily therapy: less is more
    G Moyle
    HIV Research Department, Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 14:1-5. 2003
    ..The range of once-daily options is expanding rapidly, with the potential for two lines of once-daily therapy to be available in the next 12-18 months...
  8. doi request reprint Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection
    Graeme Moyle
    HIV Research Chelsea and Westminster Hospital, London, United Kingdom
    AIDS Patient Care STDS 22:459-71. 2008
    ....
  9. ncbi request reprint Managing HIV lipoatrophy
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    Lancet 363:412-4. 2004
  10. ncbi request reprint Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    Clin Ther 26:92-7. 2004
    ..The management of anemia and neutropenia has improved survival in persons with HIV...
  11. ncbi request reprint Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection
    Graeme J Moyle
    Chelsea and Westminster Hospital, London, United Kingdom
    J Infect Dis 191:866-72. 2005
    ..The determination of coreceptor tropism may be required before CCR5 or CXCR4 antagonists are initiated, unless reliable predictive markers of coreceptor use are established...
  12. ncbi request reprint A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection
    G J Moyle
    Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK
    HIV Med 5:82-7. 2004
    ..The substance is widely used in medical applications including cosmetic procedures...
  13. ncbi request reprint Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study
    Graeme J Moyle
    Chelsea and Westminster Hospital, HIV Clinic, London, United Kingdom
    J Acquir Immune Defic Syndr 38:417-25. 2005
    ..7%). ABC administered once daily in combination with 3TC and EFV administered once daily was non-inferior to the ABC twice-daily dosing schedule when combined with 3TC and EFV over 48 weeks...
  14. ncbi request reprint Plastic surgical approaches for HIV-associated lipoatrophy
    Graeme J Moyle
    Department of HIV Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    Curr HIV/AIDS Rep 2:127-31. 2005
    ..Surgical fillers, which may be either permanent or biodegradable, are the mainstay of cosmetic management. These treatments not only lead to improved physical appearance but also may reduce social anxiety and depression...
  15. ncbi request reprint Mechanisms of HIV and nucleoside reverse transcriptase inhibitor injury to mitochondria
    Graeme Moyle
    St Stephens HIV Research, Chelsea and Westminster Hospital, London, UK
    Antivir Ther 10:M47-52. 2005
    ..There remains a need for the development of rapid, cheap and clinically applicable assays that would enable the prediction of increased likelihood of mt events...
  16. ncbi request reprint Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy
    G J Moyle
    Department of HIV Medicine, Chelsea and Westminster Hospital, London, UK
    HIV Med 7:181-5. 2006
    ..We evaluated the long-term safety and efficacy of injectable poly-L-lactic acid (PLLA) for the correction of facial lipoatrophy...
  17. ncbi request reprint Unexpected drug interactions and adverse events with antiretroviral drugs
    Graeme Moyle
    Chelsea and Westminster Hospital, London SW10 9NH, UK
    Lancet 364:8-10. 2004
  18. ncbi request reprint An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 11:73-8. 2006
    ..To examine the antiviral potency and tolerability profile of a single-class four drug (quadruple) nucleoside reverse transcriptase inhibitor (NRTI) regimen compared with a 2-class standard-of-care regimen...
  19. ncbi request reprint Changes in sleep quality and brain wave patterns following initiation of an efavirenz-containing triple antiretroviral regimen
    G Moyle
    Chelsea and Westminster Hospital, London, UK
    HIV Med 7:243-7. 2006
    ..Assessment of sleep using the electroencephalogram and electromyogram enables sleep staging to be performed and changes following the introduction of therapy to be evaluated...
  20. ncbi request reprint A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy
    Graeme J Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS 20:2043-50. 2006
    ..Peripheral fat loss, lipoatrophy, appears most associated with prolonged therapy with thymidine nucleoside analogues...
  21. ncbi request reprint Stopping HIV fusion with enfuvirtide: the first step to extracellular HAART
    Graeme Moyle
    HIV Research Department, Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 51:213-7. 2003
  22. ncbi request reprint Overcoming obstacles to the success of protease inhibitors in highly active antiretroviral therapy regimens
    Graeme Moyle
    Kobler Center, Chelsea Westminster Hospital, London, United Kingdom
    AIDS Patient Care STDS 16:585-97. 2002
    ..Atazanavir does not cause the lipid elevations seen with current PIs, and it may improve adherence through once-daily dosing...
  23. ncbi request reprint Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS Rev 12:3-14. 2010
    ..In summary, the prevention and management of visceral adiposity remains a substantial challenge in clinical practice...
  24. ncbi request reprint Anaemia in persons with HIV infection: prognostic marker and contributor to morbidity
    Graeme Moyle
    HIV Clinic, Chelsea and Westminster Hospital, London SW10 9NH, UK
    AIDS Rev 4:13-20. 2002
    ..Recombinant human erythropoietin (rHuEPO) is an effective means of improving haemoglobin and reducing transfusion requirements in patients who have low (< 500 IU/L) endogenous erythropoietin levels...
  25. ncbi request reprint Resistance and cross-resistance to abacavir
    G Moyle
    HIV Research, Chelsea and Westminster Hospital, London, UK
    HIV Med 2:154-62. 2001
    ....
  26. ncbi request reprint Principles and practice of HIV-protease inhibitor pharmacoenhancement
    G J Moyle
    Chelsea and Westminster Hospital, London and University of Liverpool, Liverpool, UK
    HIV Med 2:105-13. 2001
    ..Head-to-head clinical comparisons of boosted PI regimens will help answer some of the questions that remain with regard to PK enhancement...
  27. pmc Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV
    G J Moyle
    Kobler Clinic, Chelsea and Westminster Hospital, 369 Fulham Rd, London SW10 9NH, UK
    Br J Clin Pharmacol 54:178-82. 2002
    ..To evaluate the potential pharmacokinetic interaction between the HIV protease inhibitor saquinavir and rifabutin...
  28. ncbi request reprint The emerging roles of non-nucleoside reverse transcriptase inhibitors in antiretroviral therapy
    G Moyle
    HIV Research, Chelsea and Westminster Hospital, London, England
    Drugs 61:19-26. 2001
    ..The majority of adverse events with NNRTIs occur within the first month, and are predictable and manageable without therapy interruption...
  29. ncbi request reprint Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism?
    G Moyle
    Chelsea and Westminster Hospital, London, England
    Drug Saf 23:467-81. 2000
    ..New research evaluating the effects of long term exposure of cell lines is required to address the possibility that nuclear genotoxicity plays a role in long term nucleoside analogue toxicity...
  30. ncbi request reprint Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy
    G V Matthews
    Chelsea and Westminster Hospital, London, U K
    J Acquir Immune Defic Syndr 24:310-5. 2000
    ..In conclusion, no differences were observed between choice of drug or combination on cholesterol or triglyceride values during therapy. Older individuals may be more likely to have elevated cholesterol values...
  31. doi request reprint Proof of activity with AMD11070, an orally bioavailable inhibitor of CXCR4-tropic HIV type 1
    Graeme Moyle
    Chelsea Westminster Hospital, London, United Kingdom
    Clin Infect Dis 48:798-805. 2009
    ..The X4 Antagonist Concept Trial investigates the safety and antiviral activity of AMD11070, a potent inhibitor of X4-tropic human immunodeficiency virus (HIV) in vitro in HIV-infected patients harboring X4-tropic virus...
  32. ncbi request reprint Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity
    G Moyle
    Chelsea and Westminster Hospital, London, United Kingdom
    Clin Ther 22:911-36; discussion 898. 2000
    ..This article reviews the clinical manifestations of mitochondrial toxicity associated with the use of nucleoside analog reverse transcriptase inhibitors (NRTIs) and outlines strategies to manage these sequelae...
  33. pmc Phase 2a randomized controlled trial of short-term activity, safety, and pharmacokinetics of a novel nonnucleoside reverse transcriptase inhibitor, RDEA806, in HIV-1-positive, antiretroviral-naive subjects
    Graeme Moyle
    Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, United Kingdom
    Antimicrob Agents Chemother 54:3170-8. 2010
    ..RDEA806 is a potent and promising novel NNRTI...
  34. ncbi request reprint Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects
    K Singh
    St Stephen s Centre, Chelsea and Westminster NHS Foundation Trust, London, UK
    Clin Pharmacol Ther 83:867-72. 2008
    ..No grade 3/4 toxicity or lab abnormalities were observed. In the presence of omeprazole, saquinavir plasma exposure is significantly increased in HIV-infected subjects whether administered simultaneously or 2 h apart...
  35. doi request reprint Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz
    Vanessa Cooper
    Department of Practice and Policy, Centre for Behavioural Medicine, The School of Pharmacy, University of London, London, UK
    AIDS Care 23:705-13. 2011
    ..Switching from CBV to TVD may improve patient reported outcomes including slightly better adherence, a greater reduction in concerns about adverse effects and less treatment intrusiveness...
  36. ncbi request reprint Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens
    P J Easterbrook
    Department of HIV and Genitourinary Medicine, The Guy s, King s, and St Thomas School of Medicine, King s College Hospital Denmark Hill Campus, London, United Kingdom
    J Acquir Immune Defic Syndr 27:350-64. 2001
    ..The effectiveness of different protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors outside the setting of clinical trials has not been well described...
  37. pmc Loss of the CD56hiCD16- NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone
    M R Goodier
    Department of Immunology, Imperial College London, Faculty of Medicine, Chelsea and Westminster Hospital, London, UK
    Clin Exp Immunol 134:470-6. 2003
    ..Furthermore, in these individuals HAART with growth hormone resulted in an enhancement of cytokine-driven NK cell activation and IFN-gamma production compared to the HAART-only baseline...
  38. ncbi request reprint Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy
    A K Sullivan
    Department of Immunology, ICSTM, Chelsea and Westminster Hospital, London, UK
    Scand J Immunol 57:600-7. 2003
    ....
  39. ncbi request reprint Antiretroviral therapy for HIV-2 infected patients
    N A Smith
    Chelsea Hospital, London, UK
    J Infect 42:126-33. 2001
    ..The timing of therapy initiation, monitoring of response and the measurement of resistance remain unresolved issues and conclusions cannot be extrapolated from HIV-1...
  40. ncbi request reprint A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study)
    Chloe Orkin
    The St Stephen s Centre, The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH
    J Antimicrob Chemother 55:246-51. 2005
    ..Research is required on the effectiveness of quadruple therapy in comparison to this and the relative effectiveness of specific highly active antiretroviral therapy (HAART) combinations...
  41. ncbi request reprint Matched case-control study to evaluate risk factors for hyperlactataemia in HIV patients on antiretroviral therapy
    D Datta
    Kobler Clinic, Chelsea and Westminster Hospital, London, UK
    HIV Med 4:311-4. 2003
    ..The aim of this matched case-control study was to identify risk factors for hyperlactataemia requiring screening...
  42. ncbi request reprint Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance
    Marta Boffito
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    AIDS 21:1449-55. 2007
    ..Cumulative antiretroviral exposure can result in multiclass HIV drug resistance. Experimental antiretroviral agents offer limited therapeutic benefit as resistance quickly develops after their introduction as a sole new agent...
  43. ncbi request reprint Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial
    Desmond Maitland
    Chelsea and Westminster Hospital, London, UK
    AIDS 19:1183-8. 2005
    ....
  44. ncbi request reprint Use of HIV protease inhibitors as pharmacoenhancers
    G Moyle
    Chelsea and Westminster Hospital, London
    AIDS Read 11:87-98; quiz 107-8. 2001
    ....
  45. ncbi request reprint British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy
    A Pozniak
    Chelsea and Westminster Hospital, London, UK
    HIV Med 4:1-41. 2003
  46. ncbi request reprint Double "d" drug danger
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 13:15-6, 23-4. 2003
  47. ncbi request reprint Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients
    Lauro J Waters
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Antivir Ther 12:825-30. 2007
    ..This study investigated the steady-state plasma pharmacokinetics of abacavir when co-administered with atazanavir/ritonavir or lopinavir/ritonavir in HIV-infected individuals...
  48. ncbi request reprint The clades of HIV: their origins and clinical significance
    Justin Stebbing
    The St Stephen s Centre, The Chelsea and Westminster Hospital, London, United Kingdom
    AIDS Rev 5:205-13. 2003
    ..Efficient targeting of the extreme genetic diversity of HIV-1, and an understanding of the processes underlying this, represents one of the major challenges in the control of this ongoing pandemic...
  49. pmc Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    Br J Clin Pharmacol 59:38-42. 2005
    ..To investigate whether the administration of tenofovir diproxil fumarate 300 mg once daily alters the plasma pharmacokinetics of the saquinavir hard gel/ritonavir combination in HIV-1 infected individuals...
  50. ncbi request reprint Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials
    A Hill
    Department of Pharmacology, University of Liverpool, Liverpool, UK
    HIV Med 8:259-64. 2007
    ....
  51. ncbi request reprint The Assessing Patients' Preferred Treatments (APPT-1) study
    G Moyle
    HIV Research Department, Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 14:34-6. 2003
    ..504 people with HIV participated. Participants showed a preference for once-daily therapy administration. However, several factors affected this preference...
  52. ncbi request reprint Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 37:1376-84. 2004
    ..This study evaluated the steady-state pharmacokinetics of saquinavir 1000 mg twice daily (bid) and fosamprenavir 700 mg bid administered with 2 different doses of ritonavir (100 and 200 mg bid) in HIV-1-infected subjects...
  53. ncbi request reprint Abacavir/lamividune combination in the treatment of HIV-1 infection: a review
    Laura Waters
    St Stephen s Centre, Chelsea and Westminster Hospital, London, SW10 9NH, UK
    Expert Opin Pharmacother 7:2571-80. 2006
    ..This article reviews the pharmacology, efficacy, resistance profiles, safety and tolerability of abacavir focussing on its use in combination with lamivudine and discusses the role of this nucleoside backbone in antiretroviral therapy...
  54. doi request reprint The impact of HIV tropism on decreases in CD4 cell count, clinical progression, and subsequent response to a first antiretroviral therapy regimen
    Laura Waters
    St Stephens AIDS Trust, Department of Genitourinary HIV Medicine, Chelsea and Westminster Hospital, London, United Kingdom
    Clin Infect Dis 46:1617-23. 2008
    ..Viruses may be R5 tropic, X4 tropic, or dual/mixed (D/M) tropic. R5-tropic virus predominates at high CD4 cell counts, with the number of X4-tropic strains increasing as CD4 cell count decreases...
  55. doi request reprint Antiretroviral therapy with heart
    Paul Randell
    Department of HIV and Genitourinary Medicine, Chelsea and Westminster Hospital, London, UK
    Am J Ther 16:579-84. 2009
    ..Initiating, or switching to, ART with a lower potential for metabolic derangement should also be considered...
  56. ncbi request reprint Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses
    Marta Boffito
    Chelsea and Westminster Hospital, London, United Kingdom
    AIDS Res Hum Retroviruses 22:749-56. 2006
    ..Atazanavir-related hyperbilirubinemia was dose dependent. However, higher saquinavir and atazanavir exposure may be required to suppress HIV-resistant strain replication...
  57. ncbi request reprint The switching spiral: a triumph of hope over benefit?
    Graeme Moyle
    Chelsea and Westminster Hospital, London
    AIDS Read 12:147-50. 2002
  58. ncbi request reprint Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy
    Antonio Pires
    Department of Immunology, Imperial College, Chelsea and Westminster Hospital, London, UK
    Antivir Ther 9:67-75. 2004
    ..Administration of antiretroviral therapy (ART) during the chronic phases of HIV-1 infection fails to restore these responses in most patients...
  59. ncbi request reprint HIV-associated lipodystrophy, metabolic complications, and antiretroviral toxicities
    Graeme Moyle
    Chelsea and Westminster Hospital, London, United Kingdom
    HIV Clin Trials 3:89-98. 2002
  60. doi request reprint Screening for chronic comorbid diseases in people with HIV: the need for a strategic approach
    B Peters
    Department of Infectious Diseases, King s College London, London, UK
    HIV Med 14:1-11. 2013
    ..Health-based social networking offers a mechanism for dissemination of such a tool and is able to embed educational messages and support within the process...
  61. doi request reprint Baseline data from the MSM Neurocog study
    T Barber
    St Stephen s AIDS Trust, Chelsea and Westminster Hospital, London, UK
    J Int AIDS Soc 15:18176. 2012
    ..Subjective concerns do not translate into confirmed NCI. Patient pathways should include screening for anxiety/depression and substance use, but in this young MSM group concerns regarding memory/functional impairment seem unfounded...
  62. ncbi request reprint Mitochondrial toxicity: myths and facts
    Graeme Moyle
    The Chelsea and Westminster Hospital, London SW10 9NH, UK
    J HIV Ther 9:45-7. 2004
    ..At present, therefore, interruption of nucleoside analogue therapy, or substitution of the probable causative agent with nucleoside analogues which appear better tolerated represent the mainstay of management...
  63. ncbi request reprint Does atazanavir cause lipodystrophy?
    Brian G Gazzard
    The Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J HIV Ther 9:41-4. 2004
    ..This feature has been widely interpreted as implying that in the future there will be no abnormalities associated with fat redistribution when the drug is administered. This article explores that view...
  64. ncbi request reprint Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently: a cohort and case-control study
    Rachael Jones
    Department of HIV and Genitourinary Medicine, The Chelsea and Westminster Hospital, London, United Kingdom
    J Acquir Immune Defic Syndr 37:1489-95. 2004
    ..We investigated the overall incidence and risk of renal dysfunction in individuals receiving tenofovir DF and compared this with other antiretrovirals...
  65. ncbi request reprint A review of the aetiology of dyslipidaemia and hyperlipidaemia in patients with HIV
    Graeme Moyle
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Int J STD AIDS 16:14-20; discussion 20-2, 41-3. 2005
  66. ncbi request reprint Time for T
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 12:240-1, 248-9, 254. 2002
  67. doi request reprint The effect of zinc sulphate supplementation on atazanavir/ritonavir-associated hyperbilirubinemia
    A Jackson
    Chelsea and Westminster Hospital, London, UK
    J Int AIDS Soc 15:18305. 2012
    ..However, a decrease in ATV concentrations was also observed. ZnSO4 supplementation may represent a useful tool in the management of ATV-related HBR...
  68. pmc Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects
    Graeme Moyle
    St Stephen s Centre, Chelsea and Westminster Hospital, London, United Kingdom
    Antimicrob Agents Chemother 53:1532-8. 2009
    ..Women had higher intracellular CBV-TP exposure than did men...
  69. ncbi request reprint Lipodystrophy: lack of agreement on definition and etiology presents a challenge to research and therapy
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 12:438, 440-2. 2002
  70. ncbi request reprint Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease
    Melanie Hart
    Department of Immunology, Imperial College, Chelsea and Westminster Hospital, London, United Kingdom
    J Immunol 178:8212-20. 2007
    ....
  71. ncbi request reprint Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation
    Marta Boffito
    St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    Antivir Ther 13:901-7. 2008
    ..We investigated the pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug intake cessation...
  72. ncbi request reprint Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients
    Jennifer Ford
    Department of Pharmacology and Therapeutics, University of Liverpool, 70 Pembroke Place, Liverpool L69 3GF, and PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, London, UK
    J Antimicrob Chemother 58:1009-16. 2006
    ..To examine cellular and plasma concentrations of atazanavir when given in combination with saquinavir/ritonavir in HIV+ patients...
  73. ncbi request reprint HIV and cardiovascular risk
    Graeme Moyle
    Chelsea and Westminster Hospital, London
    Clin Med 8:315-8. 2008
  74. ncbi request reprint Hyperlactatemia and lactic acidosis: should routine screening be considered?
    Graeme Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 12:344-8. 2002
  75. ncbi request reprint The once-a-day era is upon us
    Graeme Moyle
    Chelsea and Westminster Hospital, London
    AIDS Read 12:56-8. 2002
  76. ncbi request reprint Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily
    Marta Boffito
    PK Research Ltd, St Stephen s Centre, Chelsea and Westminster Hospital, 369 Fulham Road, London SW10 9NH, UK
    J Antimicrob Chemother 55:542-5. 2005
    ..This study examined the pharmacokinetics of twice-daily saquinavir-hg (1000 mg) in the presence of ritonavir 100 mg, dosed twice-daily and once-daily on one single occasion...
  77. ncbi request reprint Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    Antivir Ther 9:423-9. 2004
    ..To evaluate the steady-state pharmacokinetics and safety of two once-daily saquinavir/ritonavir (SQV/RTV) regimens, 1600/100 and 2000/100 mg, in HIV-positive patients...
  78. ncbi request reprint Update on antiretroviral therapy: the 15th CROI
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, USA
    AIDS Read 18:273-8, C3. 2008
  79. ncbi request reprint Tenofovir and didanosine: a dangerous liaison
    Laura Waters
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 15:403-6, 413. 2005
  80. doi request reprint Treatment of altered body composition in HIV-associated lipodystrophy: comparison of rosiglitazone, pravastatin, and recombinant human growth hormone
    Derek C Macallan
    Centre for Infection, Division of Cellular and Molecular Medicine, St George s, University of London, Cranmer Terrace, London, United Kingdom
    HIV Clin Trials 9:254-68. 2008
    ..The objective of this randomized open-label study was to compare three emerging therapies, rosiglitazone, pravastatin, and growth hormone alone and together, in men and women with HALS...
  81. ncbi request reprint Simplifying suppression: switching therapies to improve HIV disease management
    Graeme J Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 14:380-4. 2004
  82. ncbi request reprint Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    AIDS 18:1291-7. 2004
    ..To determine the pharmacokinetics of saquinavir hard-gel capsules/ritonavir/atazanavir co-administered once daily at 1600/100/300 mg in HIV-infected individuals...
  83. ncbi request reprint Can we boost enough without ritonavir?
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 14:229-30, 233-5. 2004
  84. ncbi request reprint Bridging a gap: surgical management of HIV-associated lipoatrophy
    Graeme J Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 14:472-5. 2004
  85. ncbi request reprint Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission
    Vicharn Vithayasai
    Departments of Microbiology and Infectious Diseases, Chiang Mai University Hospital, Chiang Mai, Thailand
    J Acquir Immune Defic Syndr 30:410-2. 2002
    ..Although triple therapy is the standard of care for management of HIV infection in adults, the safety of many approved antiretroviral agents in pregnancy is not currently established...
  86. ncbi request reprint Efficacy and tolerability of zalcitabine twice daily (HIVBID Study)
    F Antunes
    J Acquir Immune Defic Syndr 35:205-6. 2004
  87. ncbi request reprint Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis
    Graeme J Moyle
    AIDS 16:1086-7. 2002
  88. ncbi request reprint The impact of abacavir on lipids and lipodystrophy
    Graeme J Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 15:62-6. 2005
  89. ncbi request reprint Considerations in selecting protease inhibitor therapy
    Brian A Boyle
    Weill Medical College of Cornell University, New York, NY 10021, USA
    AIDS Rev 6:218-25. 2004
    ..Protease inhibitor characteristics and patient preferences should be considered in selecting the protease inhibitor that maximizes the opportunity for long-term efficacy and tolerability of highly active antiretroviral therapy...
  90. ncbi request reprint The K65R mutation: selection, frequency, and possible consequences
    Graeme J Moyle
    Chelsea and Westminster Hospital, London
    AIDS Read 14:595-7, 601-3. 2004
  91. ncbi request reprint Where now for Trizivir? Role of the triple-NRTI pill post-ACTG 5095
    Graeme J Moyle
    HIV Research, Chelsea and Westminster Hospital, London, UK
    AIDS Read 13:223-4, 227, 244. 2003
  92. ncbi request reprint Advances in HIV therapeutics: news from the 4th International AIDS Society Conference
    Brian A Boyle
    AIDS Read 17:484-90. 2007
  93. ncbi request reprint Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy
    Graeme J Moyle
    HIV Research and HIV GU Medicine Department, Chelsea and Westminster Hospital, London, UK
    J Acquir Immune Defic Syndr 35:367-75. 2004
    ..In conclusion, over the 12-week course of therapy, rhGH, 0.1 mg/kg DD, was superior to placebo in improving physical function, body weight, body composition, and QoL and was superior to AD dosing in restoring LBM...
  94. ncbi request reprint Pharmacokinetic considerations for combining 2 protease inhibitors
    Marta Boffito
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 14:110-2, 115-6. 2004
  95. ncbi request reprint Bone mineral abnormalities in persons with HIV infection: signal or noise?
    Kasha Singh
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 16:407-10, 413-8. 2006
    ..This may reflect the observation that BMD declines as HIV disease progresses and that this decline may be arrested and partially corrected with successful antiretroviral therapy...
  96. ncbi request reprint The role of zidovudine in development of lipoatrophy
    Graeme J Moyle
    Chelsea and Westminster Hospital, London, UK
    AIDS Read 15:591-4, 599-600, 603. 2005
  97. ncbi request reprint Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens
    Simon P Jones
    Department of Pharmacology and Therapeutics, University of Liverpool, Liverpool, United Kingdom
    J Acquir Immune Defic Syndr 40:565-72. 2005
    ....
  98. ncbi request reprint XVI International AIDS Conference: Part 1
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, USA
    AIDS Read 16:517-21. 2006
  99. ncbi request reprint Lipid abnormalities during ART: it's the drug, not the class
    Graeme J Moyle
    Chelsea and Westminster Hospital, London
    AIDS Read 14:15-6, 20-2. 2004
  100. ncbi request reprint XVI International AIDS Conference: Part 2
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, USA
    AIDS Read 16:581-4, 591-2. 2006
  101. ncbi request reprint Recent developments in HIV therapeutics
    Brian A Boyle
    Department of International Medicine and Infectious Diseases, New York Presbyterian Hospital Weill Medical College of Cornell University, New York, USA
    AIDS Read 17:162-6, C3. 2007